Carlos Martínez-Chinchilla Lucía Vazquez-Montero Natalia Palazón-Carrión Isabel M Fernández-Román José López-Barba Luis de la Cruz-Merino Jesús Rodríguez-Baño Zaira R Palacios-Baena
10.3389/fimmu.2022.860891
Front Immunol
2022 Apr 14;13:860891.
covid-19 sars-cov-2 anti-cd20 case report immunocompromised lymphoma rituximab
CC BY
https://pubmed.ncbi.nlm.nih.gov/35493500/
COVID-19 Drug Treatment Lymphoma, B-Cell / drug therapy
COVID-19 Drug Treatment Lymphoma, B-Cell / drug therapy Case Reports Randomized Controlled Trial Research Support, Non-U.S. Gov't Antibodies, Monoclonal Humans Immunocompromised Host Immunosuppressive Agents Rituximab / therapeutic use SARS-CoV-2 Antibodies, Monoclonal Immunosuppressive Agents Rituximab
PMC9046988
35493500
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
2022